Laurie B. Keating

2019 - Alnylam Pharmaceuticals

In 2019, Laurie B. Keating earned a total compensation of $2.4M as Executive Vice President, Chief Legal Officer and Secretary at Alnylam Pharmaceuticals, a 50% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$268,750
Option Awards$1,272,688
Salary$490,400
Stock Awards$354,110
Other$35,732
Total$2,421,680

Keating received $1.3M in option awards, accounting for 53% of the total pay in 2019.

Keating also received $268.8K in non-equity incentive plan, $490.4K in salary, $354.1K in stock awards and $35.7K in other compensation.

Rankings

In 2019, Laurie B. Keating's compensation ranked 4,993rd out of 13,971 executives tracked by ExecPay. In other words, Keating earned more than 64.3% of executives.

ClassificationRankingPercentile
All
4,993
out of 13,971
64th
Division
Manufacturing
1,857
out of 5,695
67th
Major group
Chemicals And Allied Products
654
out of 2,194
70th
Industry group
Drugs
552
out of 1,880
71st
Industry
Pharmaceutical Preparations
412
out of 1,392
70th
Source: SEC filing on April 2, 2021.

Keating's colleagues

We found five more compensation records of executives who worked with Laurie B. Keating at Alnylam Pharmaceuticals in 2019.

2019

John Maraganore

Alnylam Pharmaceuticals

Chief Executive Officer

2019

Jeffrey Poulton

Alnylam Pharmaceuticals

Chief Financial Officer

2019

Yvonne Greenstreet

Alnylam Pharmaceuticals

Chief Operating Officer

2019

Barry Greene

Alnylam Pharmaceuticals

Former President

2019

Akshay Vaishnaw

Alnylam Pharmaceuticals

President, Research and Development

News

In-depth

You may also like